Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
Sema4 (Nasdaq: SMFR) will release its second quarter 2022 financial results on August 15, 2022, after market close. A conference call with CEO Katherine Stueland and Interim CFO Richard Miao is scheduled for the same day at 4:30 p.m. ET to discuss the results. Sema4 focuses on AI-driven genomic data and health intelligence, aiming to enhance healthcare through personalized insights. Investors can access a live and archived webcast of the call on the Sema4 investor relations website.
- Scheduled conference call to discuss financial results, enhancing transparency.
- Focus on AI-driven genomic data positions Sema4 for growth opportunities.
- None.
STAMFORD, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the second quarter of 2022 after the market close on Monday, August 15, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Richard Miao, Interim Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET.
Conference Call Details
Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the Sema4 investor relations website at https://ir.sema4.com/.
About Sema4
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.
Investor Relations Contact:
Joel Kaufman
Sema4
investors@sema4.com
Media Contact:
Radley Moss
Sema4
radley.moss@sema4.com
FAQ
When will Sema4 report its Q2 2022 earnings?
What time is the Sema4 conference call for Q2 results?
How can I listen to the Sema4 earnings call?
What is the stock symbol for Sema4?
